ArticleCancers2021

The Novel Oral mTORC1/2 Inhibitor TAK-228 Reverses Trastuzumab Resistance in HER2-Positive Breast Cancer Models.

Marta Sanz-Álvarez et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.